RESUMEN
Candida albicans, a ubiquitous commensal fungus that colonizes human mucosal tissues and skin, can become pathogenic, clinically manifesting most commonly as oropharyngeal candidiasis and vulvovaginal candidiasis (VVC). Studies in mice and humans convincingly show that T-helper 17 (Th17)/interleukin 17 (IL-17)-driven immunity is essential to control oral and dermal candidiasis. However, the role of the IL-17 pathway during VVC remains controversial, with conflicting reports from human data and mouse models. Like others, we observed induction of a strong IL-17-related gene signature in the vagina during estrogen-dependent murine VVC. As estrogen increases susceptibility to vaginal colonization and resulting immunopathology, we asked whether estrogen use in the standard VVC model masks a role for the Th17/IL-17 axis. We demonstrate that mice lacking IL-17RA, Act1, or interleukin 22 showed no evidence for altered VVC susceptibility or immunopathology, regardless of estrogen administration. Hence, these data support the emerging consensus that Th17/IL-17 axis signaling is dispensable for the immunopathogenesis of VVC.
Asunto(s)
Candidiasis Vulvovaginal/inmunología , Estrógenos/administración & dosificación , Interleucina-17/inmunología , Receptores de Interleucina-17/inmunología , Receptores de Interleucina/inmunología , Animales , Candida albicans , Candidiasis Bucal/inmunología , Candidiasis Bucal/patología , Candidiasis Vulvovaginal/patología , Modelos Animales de Enfermedad , Estrógenos/metabolismo , Femenino , Ratones , Ratones Endogámicos C57BL , Membrana Mucosa/patología , Transducción de Señal/inmunología , Vagina/microbiologíaRESUMEN
Transcription profiles of genes of local immune response were determined in the vagina of women with bacterial vaginosis, aerobic vaginitis, and vulvovaginal candidosis for detection of the most specific immune markers for these vaginal infections. Laboratory diagnosis of the vaginal infections was performed microscopically; the inflammatory reaction in the vagina (leukorrhea) was defined as the presence of >10 white blood cells per field of view. Transcription profiles of IL1b, IL10, IL18, TNFα, TLR4, GATA3, and CD68 were determined using reverse-transcription quantitative real-time PCR. The strongest predictors of aerobic vaginitis were increased levels of IL1b and IL10 mRNA. Bacterial vaginosis was strongly associated with reduced levels of IL18 and GATA3 mRNA. Increased levels of IL1b and TLR4 transcripts showed significant discriminatory power for vulvovaginal candidosis and leukorrhea. The results of this study suggest differential expression of local immune response genes in the vagina of women with different vaginal infections. Detection of specific immune markers in the vagina using reverse-transcriptase PCR could supplement PCR detection of abnormal vaginal microflora for the diagnosis of vaginal infections.
Asunto(s)
Inmunidad Adaptativa/genética , Vagina/inmunología , Vagina/metabolismo , Vaginosis Bacteriana/diagnóstico , Adulto , Biomarcadores/análisis , Biomarcadores/metabolismo , Candidiasis Vulvovaginal/diagnóstico , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Estudios de Casos y Controles , Femenino , Regulación de la Expresión Génica , Humanos , Inflamación/genética , Inflamación/inmunología , Inflamación/metabolismo , Interleucina-10/genética , Interleucina-10/metabolismo , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Receptor Toll-Like 4/genética , Receptor Toll-Like 4/metabolismo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo , Vagina/patología , Vaginosis Bacteriana/genética , Vaginosis Bacteriana/inmunología , Vaginosis Bacteriana/microbiologíaRESUMEN
Vulvovaginal candidiasis (VVC) is a common observed infection, affecting approximately 75% of women of reproductive age. Drug resistance represents a troublesome stumbling block associated with VVC therapy. Thus the aim of the present study was to provide information regarding the selection of potential drug targets for VVC. CXCR3-, CXCR4-, or CXCR/CXCR4 double-deficient mouse models of VVC were subsequently established, with changes to the load of Candida Albicans evaluated accordingly. The biological behaviors of the vaginal epithelial cells were characterized in response to the CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout in vivo. Our initial observations revealed that in mice with VVC, CXCR3-, CXCR4-, or CXCR3 - CXCR4 double-knockout resulted in a decreased load of C. Albicans as well as reduced levels and proportion of Th17 cells. Proinflammatory cytokine production was found to be inhibited by CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout whereby the mRNA and protein expressions CXCR3, CXCR4, IL-17, IL-6, and TNF-α exhibited decreased levels. CXCR3-, CXCR4-, or CXCR3/CXCR4 double-knockout appeared to function as positive proliferation factors, while playing a negative role in the processes of apoptosis and the cell cycle of vaginal epithelial cells. Taken together, the key findings of the study suggested that CXCR3/CXCR4 double-knockout could act to hinder the progression of VVC, highlighting its promise as a novel therapeutic target in the treatment of VVC. CXCR3 and CXCR4 genes may regulate Th17/IL-17 immune inflammatory pathways to participate in antifungal immunity.
Asunto(s)
Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/metabolismo , Citocinas/biosíntesis , Mediadores de Inflamación/metabolismo , Receptores CXCR3/deficiencia , Receptores CXCR4/deficiencia , Células Th17/patología , Animales , Apoptosis , Candida albicans/fisiología , Candidiasis Vulvovaginal/sangre , Candidiasis Vulvovaginal/microbiología , Ciclo Celular , Proliferación Celular , Citocinas/sangre , Células Epiteliales/metabolismo , Células Epiteliales/microbiología , Células Epiteliales/patología , Femenino , Ratones Noqueados , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores CXCR3/sangre , Receptores CXCR3/metabolismo , Receptores CXCR4/sangre , Receptores CXCR4/metabolismo , Vagina/microbiología , Vagina/patologíaRESUMEN
Vulvovaginal candidiasis (VVC) affects approximately 75% of all women of during their reproductive years. Previously, we reported that recombinant human IFN α-2b (rhIFNα-2b) protects vaginal epithelial cells from candidal injury in vitro. In the current study, we examined the effects of rhIFNα-2b (1.25â¯mg/mL, 10% inhibition concentration) on fungal clearance, immunocompetent cytokine responses, non-B IgG production, and tissue repair in a rat model of VVC. Following rhIFNα-2b treatment, the negative pathogen conversion rate reached 50.0% (3/6). Although rhIFNα-2b exhibited a limited ability to decrease inflammation and injury progression (Pâ¯>â¯0.05), the Flameng mitochondrial injury scores were significantly reduced (Pâ¯<â¯0.001) compared with those of the Model rats. After rhIFNα-2b treatment, the levels of IFN-γ and epithelial-derived IgG (tested by RP215) in vaginal tissues were significantly increased with those in the Control and Model groups (both Pâ¯<â¯0.001), while there were no significant differences in the levels of IL-4 and IL-17 (Pâ¯>â¯0.05). This is the first study to address the efficacy of rhIFNα-2b in treating VVC in a rat model, providing a theoretical basis for development of this promising treatment for clinical use.
Asunto(s)
Candidiasis Vulvovaginal/tratamiento farmacológico , Interferón Tipo I/uso terapéutico , Interferón alfa-2/uso terapéutico , Animales , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/patología , Citocinas/uso terapéutico , Modelos Animales de Enfermedad , Células Epiteliales/microbiología , Células Epiteliales/patología , Femenino , Humanos , Inmunoglobulina G , Inflamación/tratamiento farmacológico , Interferón Tipo I/administración & dosificación , Interferón alfa-2/administración & dosificación , Interleucina-17 , Interleucina-4 , Nistatina/uso terapéutico , Ratas , Ratas Sprague-Dawley , Vagina/microbiologíaRESUMEN
Objective: To study the disease process of vulvovaginal candidiasis (VVC) infection in rat model of VVC, and to study the immuno-repairing effect of different treatments on vaginal epithelium and the ultra-structural changes of vaginal epithelial cells. Methods: The VVC model of female rats were established. After successful modeling, the rats were treated with no treatment (model control group), nystatin and Kangfu Xiaoyan suppository. The vaginal epithelium was observed by transmission electron microscopy and immunohistochemical staining. The ultra-structural changes of epithelial cells and the expression of cytokines interferon γ (IFN-γ), interleukin (IL) 4, IL-17 and IgG in epithelial cells were observed and analyzed statistically. Results: The negative conversion rate of model control group was 0, and that of nystatin group was 6/6, and that of Kangfu Xiaoyan suppository group was 5/6; significant difference existed between nystatin, Kangfu Xiaoyan suppository group and model control group (P<0.05). The ultrastructures of vaginal epithelial cells were damaged obviously after VVC infection, and the ultrastructures were repaired by nystatin and Kangfu Xiaoyan suppository under transmission electron microscope. Immunohistochemical staining showed, the expressions of IFN-γ and IgG in the four cytokines which played a protective role increased after Kangfu Xiaoyan suppository treatment, significantly different from that of model control group (P<0.05), but there were no significant differences of the IFN-γ and IgG expression between Kangfu Xiaoyan suppository group and those of nystatin group (P>0.05); the expression of IL-17 was increased after nystatin treatment, but decreased after Kangfu Xiaoyan suppository treatment, and the difference between the two groups had statistical significance (P<0.05). Conclusions: The ultrastructure of vaginal epithelial cells after VVC infection could be damaged obviously, the local immune state is disordered, and the antifungal drug nystatin has a good therapeutic effect on VVC, it could significantly repair the damaged vaginal epithelium structure after VVC infection and strengthen the protective immune function of vaginal epithelium. Kangfu Xiaoyan suppository, one of Chinese medicine, has similar therapeutic effect with nystatin.
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis Vulvovaginal/tratamiento farmacológico , Nistatina/uso terapéutico , Vagina/microbiología , Animales , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Citocinas , Femenino , Humanos , Ratas , SupositoriosRESUMEN
For over 3 decades, investigators have studied the pathogenesis of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) through clinical studies and animal models. While there was considerable consensus that susceptibility was not associated with any apparent deficiencies in adaptive immunity, protective immune mechanisms and the role of innate immunity remained elusive. It was not until an innovative live-challenge design was conducted in women that a fuller understanding of the natural history of infection/disease was achieved. These studies revealed that symptomatic infection is associated with recruitment of polymorphonuclear neutrophils (PMNs) into the vaginal lumen. Subsequent studies in the established mouse model demonstrated that infiltrating PMNs were incapable of reducing the fungal burden, which supported the hypothesis that VVC/RVVC was an immunopathology, whereby Candida and the host response drive symptomatic disease. Further studies in mice revealed the requirement for C. albicans hyphae and identified pattern recognition receptors (PRRs) and proinflammatory mediators responsible for the PMN response, all of which are critical pieces of the immunopathogenesis. However, a mechanism explaining PMN dysfunction at the vaginal mucosa remained an enigma. Ultimately, by employing mouse strains resistant or susceptible to chronic VVC, it was determined that heparan sulfate (HS) in the vaginal environment of susceptible mice serves as a competitive ligand for Mac-1 on PMNs, which effectively renders the PMNs incapable of binding to Candida to initiate killing. Hence, the outcome of symptomatic VVC/RVVC is postulated to be dependent on a PMN-mediated immunopathogenic response involving HS that effectively places the neutrophils in a state of functional anergy.
Asunto(s)
Candida albicans/fisiología , Candidiasis Vulvovaginal/inmunología , Neutrófilos/inmunología , Animales , Candidiasis Vulvovaginal/microbiología , Candidiasis Vulvovaginal/patología , Femenino , Humanos , Infiltración Neutrófila , Vagina/inmunología , Vagina/microbiología , Vagina/patologíaRESUMEN
The human fungal pathogen Candida albicans is the major etiological agent of vulvovaginal candidiasis (VVC). Despite this fact, other non-albicans Candida (NAC) species have frequently been reported, as well. Despite their presence in the vaginal environment, little is known about their capacities to elicit immune responses classically associated with C. albicans-mediated immunopathology, including neutrophil recruitment and proinflammatory cytokine signaling. Therefore, using a combination of in vitro and in vivo approaches, we undertook a comparative analysis to determine whether a representative panel of NAC species could colonize, induce immunopathological markers, or cause damage at the vaginal mucosa. Using a murine model of VVC, C. albicans was found to induce robust immunopathology (neutrophils and interleukin 1ß [IL-1ß]) and elicit mucosal damage. However, all the NAC species tested (including C. dubliniensis, C. tropicalis, C. parapsilosis, C. krusei, C. glabrata, and C. auris) induced significantly less damage and neutrophil recruitment than C. albicans, despite achieving similar early colonization levels. These results largely correlated with a notable lack of ability by the NAC species (including C. dubliniensis and C. tropicalis) to form hyphae both in vitro and in vivo Furthermore, both C. dubliniensis and C. tropicalis induced significantly less expression of the ECE1 gene encoding candidalysin, a key fungal virulence determinant driving VVC immunopathology. In order to determine the relative capacities of these species to elicit inflammasome-dependent IL-1ß release, both wild-type and NLRP3-/- THP-1 cells were challenged in vitro While most species tested elicited only modest amounts of IL-1ß, challenge with C. albicans led to significantly elevated levels that were largely NLRP3 dependent. Collectively, our findings demonstrate that although NAC species are increasingly reported as causative agents of VVC, C. albicans appears to be exceedingly vaginopathogenic, exhibiting robust immunopathology, hypha formation, and candidalysin expression. Thus, this study provides mechanistic insight into why C. albicans is overwhelmingly the major pathogen reported during VVC.
Asunto(s)
Candida/patogenicidad , Candidiasis Vulvovaginal/microbiología , Vagina/inmunología , Vagina/patología , Animales , Candida glabrata/patogenicidad , Candida tropicalis/patogenicidad , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/patología , Citocinas/inmunología , Modelos Animales de Enfermedad , Femenino , Proteínas Fúngicas/genética , Inflamasomas , Interleucina-1beta/inmunología , Ratones , Ratones Endogámicos C57BL , Membrana Mucosa/inmunología , Membrana Mucosa/microbiología , Membrana Mucosa/patología , Infiltración Neutrófila , Transducción de Señal/inmunología , Vagina/microbiología , Factores de VirulenciaRESUMEN
Unlike other forms of candidiasis, vulvovaginal candidiasis, caused primarily by the fungal pathogen Candida albicans, is a disease of immunocompetent and otherwise healthy women. Despite its prevalence, the fungal factors responsible for initiating symptomatic infection remain poorly understood. One of the hallmarks of vaginal candidiasis is the robust recruitment of neutrophils to the site of infection, which seemingly do not clear the fungus, but rather exacerbate disease symptomatology. Candidalysin, a newly discovered peptide toxin secreted by C. albicans hyphae during invasion, drives epithelial damage, immune activation, and phagocyte attraction. Therefore, we hypothesized that Candidalysin is crucial for vulvovaginal candidiasis immunopathology. Anti-Candida immune responses are anatomical-site specific, as effective gastrointestinal, oral, and vaginal immunities are uniquely compartmentalized. Thus, we aimed to identify the immunopathologic role of Candidalysin and downstream signaling events at the vaginal mucosa. Microarray analysis of C. albicans-infected human vaginal epithelium in vitro revealed signaling pathways involved in epithelial damage responses, barrier repair, and leukocyte activation. Moreover, treatment of A431 vaginal epithelial cells with Candidalysin induced dose-dependent proinflammatory cytokine responses (including interleukin 1α [IL-1α], IL-1ß, and IL-8), damage, and activation of c-Fos and mitogen-activated protein kinase (MAPK) signaling, consistent with fungal challenge. Mice intravaginally challenged with C. albicans strains deficient in Candidalysin exhibited no differences in colonization compared to isogenic controls. However, significant decreases in neutrophil recruitment, damage, and proinflammatory cytokine expression were observed with these strains. Our findings demonstrate that Candidalysin is a key hypha-associated virulence determinant responsible for the immunopathogenesis of C. albicans vaginitis.
Asunto(s)
Candida albicans/patogenicidad , Células Epiteliales/microbiología , Proteínas Fúngicas/metabolismo , Membrana Mucosa/microbiología , Animales , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/metabolismo , Citocinas/metabolismo , Células Epiteliales/metabolismo , Femenino , Proteínas Fúngicas/farmacología , Humanos , Ratones , Membrana Mucosa/patología , Infiltración Neutrófila/inmunología , Transducción de Señal , Vagina/inmunología , Vagina/metabolismo , Vagina/microbiología , Factores de VirulenciaRESUMEN
Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration: NCT01926028.
Asunto(s)
Candidiasis Vulvovaginal/terapia , Proteínas Fúngicas/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Inmunoterapia , Adolescente , Adulto , Linfocitos B/inmunología , Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/inmunología , Método Doble Ciego , Femenino , Vacunas Fúngicas/efectos adversos , Humanos , Inmunogenicidad Vacunal , Inyecciones Intramusculares , Persona de Mediana Edad , Recurrencia , Linfocitos T/inmunología , Adulto JovenRESUMEN
BACKGROUND/AIMS: Vulvovaginal candidiasis (VVC) is a disease commonly occurring in sexually active women. The involvement of microRNAs in several kinds of infectious diseases has been highlighted in a number of researches. Therefore, we conducted the present study in order to investigate whether microRNA-1192 (miR-1192) would significantly target CXCR4 in Th17 cells as well as inflammatory factors in mouse models suffering from VVC. METHODS: Seventy-five mice were selected as test subjects for this study, of which twenty-five were used as the normal control, while the rest were treated with estradiol or oil-treated in order to establish VVC mouse models (each n = 25). Protein expressions of CXCR4, IL-6, IL-17, and IL-23 were all measured using both an immunohistochemistry and ELISA. The Th17 cell percentage in peripheral blood and the expression of RORγt in Th17 cells were detected using a flow cytometry. Mouse vaginal epithelial cells were isolated from normal mice, after which the mice were treated with estradiol to regulate their estrogen, followed by treatments involving the miR-1192 mimic, miR-1192 inhibitor, siRNA-CXCR4, and miR-1192 inhibitor + si-CXCR4. The cell cycle, apoptosis, and proliferation were all examined by using an additional flow cytometry as well as the employment of the MTT assay. The miR-1192, CXCR4, IL-6, IL-17, and IL-23 expressions in tissues and cells were both measured using both RT-qPCR and western blot assay techniques. RESULTS: The mice treated with either estradiol or oil had presented to us lowered levels in miR-1192 expression as well as higher levels in both Th17 cell percentage and expression of RORγt in Th17 cells, along with mRNA and protein expressions of CXCR4, IL-6, IL-17, and IL-23. In cell experiments, the mouse vaginal epithelial cells that had been treated with miR-1192 inhibitor had shown us a decreased cell proliferation rate and contrarily increased expressions of CXCR4, IL-6, IL-17, and IL-23 mRNA, protein, and cell apoptosis rate; these results were opposite to the ones found in the mice treated with miR-1192 mimic. CONCLUSION: Our results provided significant evidence that miR-1192 could directly development and progression of VVC by restraining the CXCR4 gene in the VVC mice.
Asunto(s)
Candidiasis Vulvovaginal/patología , MicroARNs/metabolismo , Receptores CXCR4/metabolismo , Regiones no Traducidas 3' , Animales , Antagomirs/metabolismo , Apoptosis , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Puntos de Control del Ciclo Celular , Modelos Animales de Enfermedad , Femenino , Interleucina-17/análisis , Interleucina-17/química , Interleucina-17/metabolismo , Interleucina-23/análisis , Interleucina-23/genética , Interleucina-23/metabolismo , Interleucina-6/análisis , Interleucina-6/genética , Interleucina-6/metabolismo , Ratones , Ratones Endogámicos BALB C , MicroARNs/antagonistas & inhibidores , MicroARNs/genética , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Receptores CXCR4/antagonistas & inhibidores , Receptores CXCR4/genética , Células Th17/citología , Células Th17/metabolismoRESUMEN
The female reproductive tract (FRT) presents a unique challenge to the mucosal immune system as it needs to monitor constantly for the presence of opportunistic pathogens amidst its commensal flora. During infection, autophagy plays a critical role in pathogen clearance, presentation of antigens and production of pro-inflammatory cytokines. However, no information is available that describes the role of autophagy in mouse vaginal infection of Candida albicans. The objective of our study is to evaluate the effect of autophagy gene, ATG5 knockout in vaginal cells in response to vaginal C. albicans infection. Mice having knockout of ATG5 in the vaginal cells (PR-ATG5-KO mice) were infected intra-vaginally with the yeast form of Candida albicans. Vaginal lavages were collected once in a week until the infection was cleared. We detected the expression of autophagy marker genes (LC3, ATG5 and LAMP1) in the vaginal cells. We determined the levels of various cytokines (IL-1α, IL-1ß, IL-6, IL-10, IL-17A, IL-22, IL-23p19, TNF-α and G-CSF) involved in anti-candida response. The levels of cytokines in the vaginal lavages were quantified using Aimplex Premixed analyte kit. The vaginal lavages were checked for polymorphonuclear leucocytes (PMNLs) infiltration. The candida clearance rate from the vaginal lumen was determined by Colony Forming Units (CFUs) assay. The results revealed that PR-ATG5-KO mice failed to induce the expression of LC3, ATG5 and LAMP1 indicating an impaired autophagy pathway. The levels of all the cytokines (except IL-10) in C. albicans infected PR-ATG5-KO mice were significantly reduced as compared to the wild type infected C57BL/6 mice. The number of PMNLs infiltrated into the vaginal lavages of infected PR-ATG5-KO mice was reduced. The clearance of C. albicans from the vaginal lumen was also considerably delayed in PR-ATG5-KO mice. In conclusion, the results revealed that impaired autophagy in vaginal cells influences host response during vaginal infection of C. albicans by affecting anti-Candida cytokine levels in the vaginal lavage resulting in reduction of pathogen clearance rate.
Asunto(s)
Proteína 5 Relacionada con la Autofagia/genética , Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Citocinas/inmunología , Animales , Autofagia/genética , Proteína 5 Relacionada con la Autofagia/inmunología , Candida albicans/patogenicidad , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/microbiología , Candidiasis Vulvovaginal/patología , Femenino , Técnicas de Inactivación de Genes , Interleucinas/inmunología , Ratones , Ratones Noqueados , Neutrófilos/inmunología , Células Th17/inmunologíaRESUMEN
BACKGROUND: Vulvovaginal candidiasis (VVC) is a common infectious disease of the lower genital tract. Nystatin, a polyene fungicidal antibiotic, is used as a topical antifungal agent for VVC treatment. The aim of the current study was to investigate the possible immunomodulatory effects of nystatin on the vaginal mucosal immune response during Candida albicans infection and examine its role in protection of vaginal epithelial cell (VEC) ultrastructure. RESULTS: Following infection with C. albicans, IFN-γ and IL-17 levels in VECs were significantly elevated, while the presence of IgG was markedly decreased as compared to uninfected controls (P < 0.05). No significant differences in IL4 expression were observed. After treatment with nystatin, the level of IFN-γ, IL-17 and IgG was dramatically increased in comparison to the untreated group (P < 0.05). Transmission electron microscopy revealed that C. albicans invades the vaginal epithelium by both induced endocytosis and active penetration. Nystatin treatment protects the ultrastructure of the vaginal epithelium. Compared with the untreated C. albicans-infected group, Flameng scores which measure mitochondrial damage of VECs were markedly decreased (P < 0.001) and the number of adhesive and invasive C. albicans was significantly reduced (P < 0.01) after treatment with nystatin. CONCLUSIONS: Nystatin plays a protective role in the host defense against C. albicans by up-regulating the IFN-γ-related cellular response, the IL-17 signaling pathway and possibly through enhancing VEC-derived IgG-mediated immunity. Furthermore, nystatin notably improves the ultramorphology of the vaginal mucosa, partially through the protection of mitochondria ultrastructure in VECs and inhibition of adhesion and invasion by C. albicans. Together, these effects enhance the immune response of the vaginal mucosa against C. albicans and protect the ultrastructure of vaginal epithelium in VVC rats.
Asunto(s)
Antifúngicos/uso terapéutico , Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/inmunología , Células Epiteliales/ultraestructura , Nistatina/uso terapéutico , Vagina/microbiología , Animales , Candidiasis Vulvovaginal/tratamiento farmacológico , Modelos Animales de Enfermedad , Células Epiteliales/microbiología , Femenino , Factores Inmunológicos/uso terapéutico , Interferón gamma/inmunología , Interleucina-17/inmunología , Mitofagia , Ratas , Ratas Sprague-Dawley , Vagina/ultraestructuraRESUMEN
Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level.The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.
Asunto(s)
Ácido Aspártico Endopeptidasas/inmunología , Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/patología , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/inmunología , Factores de Virulencia/inmunología , Animales , Candida albicans/enzimología , Candida albicans/patogenicidad , Candidiasis Vulvovaginal/microbiología , Candidiasis Vulvovaginal/prevención & control , Modelos Animales de Enfermedad , Femenino , Interacciones Huésped-Patógeno/inmunología , Vagina/inmunología , Vagina/microbiología , Vagina/patologíaRESUMEN
OBJECTIVE: To evaluate the efficacy of cis-2-dodecenoic acid (BDSF) in the treatment and prevention of vaginal candidiasis in vivo. METHODS: The activities of different concentrations of BDSF against the virulence factors of Candida albicans (C. albicans) were determined in vitro. An experimental mouse model of Candida vaginitis was treated with 250 µmol/L BDSF. Treatment efficiency was evaluated in accordance with vaginal fungal burden and inflammation symptoms. RESULTS: In vitro experiments indicated that BDSF attenuated the adhesion and damage of C. albicans to epithelial cells by decreasing phospholipase secretion and blocking filament formation. Treatment with 30 µmol/L BDSF reduced the adhesion and damage of C. albicans to epithelial cells by 36.9% and 42.3%, respectively. Treatment with 200 µmol/L BDSF completely inhibited phospholipase activity. In vivo mouse experiments demonstrated that BDSF could effectively eliminate vaginal infection and relieve inflammatory symptoms. Four days of treatment with 250 µmol/L BDSF reduced vaginal fungal loads by 6-fold and depressed inflammation. Moreover, BDSF treatment decreased the expression levels of the inflammatory chemokine-associated genes MCP-1 and IGFBP3 by 2.5- and 2-fold, respectively. CONCLUSION: BDSF is a novel alternative drug that can efficiently control vaginal candidiasis by inhibiting the virulence factors of C. albicans.
Asunto(s)
Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/tratamiento farmacológico , Ácidos Grasos Monoinsaturados/administración & dosificación , Animales , Candida albicans/metabolismo , Candida albicans/patogenicidad , Candida albicans/fisiología , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Quimiocina CCL2/genética , Quimiocina CCL2/inmunología , Modelos Animales de Enfermedad , Femenino , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Humanos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/inmunología , Ratones , Virulencia/efectos de los fármacos , Factores de Virulencia/genética , Factores de Virulencia/metabolismoRESUMEN
Recurrent vulvovaginal candidiasis (RVVC) is a common cause of significant morbidity in women in all strata of society affecting millions of women worldwide. Previously, RVVC occurrence was limited by onset of menopause but the widespread use of hormone replacement therapy has extended the at-risk period. Candida albicans remains the dominant species responsible for RVVC, however optimal management of RVVC requires species determination and effective treatment measures are best if species-specific. Considerable progress has been made in understanding risk factors that determine susceptibility to RVVC, particularly genetic factors, as well as new insights into normal vaginal defense immune mechanisms and their aberrations in RVVC. While effective control of RVVC is achievable with the use of fluconazole maintenance suppressive therapy, cure of RVVC remains elusive especially in this era of fluconazole drug resistance. Vaccine development remains a critical challenge and need.
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis Vulvovaginal , Candidiasis Vulvovaginal/diagnóstico , Candidiasis Vulvovaginal/tratamiento farmacológico , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Farmacorresistencia Fúngica , Femenino , Predisposición Genética a la Enfermedad , Humanos , Probióticos , RecurrenciaRESUMEN
Objective: To investigate the function of IgG secreted by vaginal epithelial cells in natural resistance to vulvovaginal candidiasis. Methods: (1)Immunohistochemical method was used to determine the expression of IgG secreted by normal vaginal epithelial cells VK2/E6E7.(2)Samples were divided into three groups by different proportions of VK2/E6E7 cells to Candida albicans ,including Candida albicans: VK2/E6E7 cells were 1â¶10, 1â¶1[yeast+ cells(1â¶10)group and yeast+ cells(1â¶1)group]and VK2/E6E7 cells as blank control group. The growth status of 3 groups were observed under inverted microscope after 24 hours. ELISA method was used to detect the production of IgG in 3 groups after 0, 3, 6, 12, 24, 48 hours. Results: (1)Immunohistochemical method showed normal vaginal epithelial cells were polygonal with pale blue nucleus and cytoplasm were distributed by brown granules, which indicated that IgG were strongly positive. While negative control group just had light blue nuclei.(2)Inverted microscope observation represented that control group had a clear outline, strong refraction and large nuclei with cobblestone-like appearance. After yeast+cells(1â¶10)group co-cultured for 24 hours, Candida albicans begin to sprout and transformed to hyphae. VK2/E6E7 cells and Candida albicans were close to each other with vacuoles and small black granules in the cytoplasm. The morphology of cells were complete. Yeast+ cells(1â¶1)group showed obvious invasion effect of Candida albicans to VK2/E6E7 cells with vigorous growth of hyphae, the decreased number and incomplete morphology of cells. Moreover, the connection of cells were loose. ELISA assay showed that there were statistically significant difference of IgG secretions between the 3 groups after 0, 3, 6, 12, 24, 48 hours(P<0.05). After stimulation of Candida albicans, secretion of IgG was significantly lower than that in the control group. The statistical difference of IgG secretions between yeast+ cells(1â¶10)group and yeast+ cells(1â¶1)group after 3, 6, 12, 24 hours were dramatic(P<0.05). The peak of IgG production showed when the ratio of Candida albicans and VK2/E6E7 was 1â¶1 after 24 hours co-cultured(1.61±0.05)µg/ml. Conclusions: Candida albicans has a significant invasion role on epithelial cells. With increasing concentrations of Candida albicans, the invasion effect will be enhenced. While, after the vaginal epithelial cells co-cultured with Candida albicans, the secretion of IgG decreased significantly.
Asunto(s)
Candida albicans/crecimiento & desarrollo , Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Células Epiteliales/metabolismo , Vagina/citología , Candida albicans/efectos de los fármacos , Candida albicans/fisiología , Candidiasis Vulvovaginal/microbiología , Técnicas de Cocultivo , Ensayo de Inmunoadsorción Enzimática , Células Epiteliales/citología , Femenino , Humanos , Inmunoglobulina G , InmunohistoquímicaRESUMEN
Candida albicans is part of the normal commensal microbiota of mucosal surfaces in a large percentage of the human population. However, perturbations of the host's immune response or bacterial microbiota have been shown to predispose individuals to the development of opportunistic Candida infections. It was recently discovered that a defect in the chemokine receptor CX3CR1 increases susceptibility of mice and humans to systemic candidiasis. However, whether CX3CR1 confers protection against mucosal C. albicans infection has not been investigated. Using two different mouse models, we found that Cx3cr1 is dispensable for the induction of interleukin 17A (IL-17A), IL-22, and IL-23 in the tongue after infection, as well as for the clearance of mucosal candidiasis from the tongue or lower gastrointestinal (GI) tract colonization. Furthermore, the dysfunctional human CX3CR1 allele CX3CR1-M280 was not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women. Taken together, these data indicate that CX3CR1 is not essential for protection of the host against mucosal candidiasis, underscoring the dependence on different mammalian immune factors for control of mucosal versus systemic Candida infections.
Asunto(s)
Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Candidiasis/inmunología , Infecciones Oportunistas/inmunología , Receptores de Quimiocina/inmunología , Alelos , Animales , Receptor 1 de Quimiocinas CX3C , Candidiasis/genética , Candidiasis/microbiología , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/microbiología , Modelos Animales de Enfermedad , Femenino , Tracto Gastrointestinal/inmunología , Tracto Gastrointestinal/microbiología , Expresión Génica , Interacciones Huésped-Patógeno , Humanos , Interleucina-17/genética , Interleucina-17/inmunología , Interleucina-23/genética , Interleucina-23/inmunología , Interleucinas/genética , Interleucinas/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Infecciones Oportunistas/genética , Infecciones Oportunistas/microbiología , Receptores de Quimiocina/deficiencia , Receptores de Quimiocina/genética , Lengua/inmunología , Lengua/microbiología , Vagina/inmunología , Vagina/microbiología , Interleucina-22RESUMEN
The ability to tolerate Candida albicans, a human commensal of the gastrointestinal tract and vagina, implicates that host defense mechanisms of resistance and tolerance cooperate to limit fungal burden and inflammation at the different body sites. We evaluated resistance and tolerance to the fungus in experimental and human vulvovaginal candidiasis (VVC) as well as in recurrent VVC (RVVC). Resistance and tolerance mechanisms were both activated in murine VVC, involving IL-22 and IL-10-producing regulatory T cells, respectively, with a major contribution by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 was responsible for the production of tolerogenic kynurenines, such that replacement therapy with kynurenines restored immunoprotection to VVC. In humans, two functional genetic variants in IL22 and IDO1 genes were found to be associated with heightened resistance to RVVC, and they correlated with increased local expression of IL-22, IDO1 and kynurenines. Thus, IL-22 and IDO1 are crucial in balancing resistance with tolerance to Candida, their deficiencies are risk factors for RVVC, and targeting tolerance via therapeutic kynurenines may benefit patients with RVVC.
Asunto(s)
Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Tolerancia Inmunológica , Inmunidad Mucosa , Indolamina-Pirrol 2,3,-Dioxigenasa/metabolismo , Interleucinas/biosíntesis , Linfocitos T Reguladores/inmunología , Animales , Candida albicans/efectos de los fármacos , Candida albicans/aislamiento & purificación , Candidiasis Vulvovaginal/genética , Candidiasis Vulvovaginal/metabolismo , Candidiasis Vulvovaginal/microbiología , Femenino , Estudios de Asociación Genética , Variación Genética , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Inmunidad Mucosa/efectos de los fármacos , Factores Inmunológicos/metabolismo , Factores Inmunológicos/uso terapéutico , Indolamina-Pirrol 2,3,-Dioxigenasa/genética , Interleucina-10/biosíntesis , Interleucinas/genética , Quinurenina/metabolismo , Quinurenina/uso terapéutico , Ratones , Ratones Endogámicos C57BL , Ratones SCID , Recurrencia , Inmunodeficiencia Combinada Grave/tratamiento farmacológico , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/fisiopatología , Organismos Libres de Patógenos Específicos , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/metabolismo , Interleucina-22RESUMEN
In vitro evaluation of specific anti-Candida albicans sera antibodies based on synthetically prepared complement receptor 3-related protein (CR3-RP) mimicking the structure of native complement receptor 3 in a cohort of 72 patients with atopy and recurrent Candida vulvovaginitis (RVC) revealed effective humoral response against Candida CR3-RP. The most significant have been IgM and IgA isotype antibodies (33 and 47% positive cases, respectively). The quantitative evaluation of anti-CR3RP isotype antibodies was confronted with results of commercial ELISA anti-C. albicans antibodies diagnostics based on C. albicans cell wall mannan and ß-glucan antigens, the most significant correlation being observed with anti-CR3-RP IgM and anti-ß-D-glucan IgM (r(2) = 0.624) followed by isotype IgA (r(2) = 0.381). The immunogenicity and immunoreactivity of CR3RP antigen in RVC patients' sera had been evaluated with regard to the results reached by counterimmunoelectrophoresis and heterogeneous enzyme immunoassay. Obviously, synthetically prepared CR3-RP mimicking the Candida cell-wall-derived structure moiety represents a promising immunological tool not only for Candida serodiagnostics, but also prospectively for follow-up of targeted antifungal therapy and as promising Candida vaccine candidate.
Asunto(s)
Anticuerpos Antifúngicos/sangre , Antígenos Fúngicos/inmunología , Candida albicans/inmunología , Candidiasis Vulvovaginal/inmunología , Proteínas Fúngicas/inmunología , Candidiasis Vulvovaginal/diagnóstico , Femenino , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina M/sangreRESUMEN
Although a number of fungal species belonging to the genus Candida can cause acute vulvovaginal infection (VVC), Candida albicans is by far the most prevalent etiological agent, particularly for the most severe chronic condition known as recurrent vulvovaginal candidiasis (RVVC). This review focuses on recent advances in pathogenic mechanisms and host immune responses to C. albicans and on the utilisation of this information in the development of a vaccine to prevent and/or treat vaginal candidiasis. Currently, two vaccines with main or sole RVVC as clinical indication have completed a phase 1 clinical trial, and one of them has entered a phase 2 trial.